,0
Abstract:,30
Infections,1
in,229
childhood,1
play,2
an,20
essential,4
role,6
the,332
pathogenesis,4
of,367
cognitive,5
and,317
psycho-emotional,1
disorders.,1
One,3
possible,4
mechanisms,9
these,7
impairments,2
is,37
changes,12
functional,4
properties,1
NMDA,3
AMPA,3
glutamate,3
receptors,3
brain.,1
We,18
suggest,4
that,33
bacterial,3
infections,4
during,11
early,13
life,3
"period,",1
which,9
critical,3
for,83
excitatory,2
synapse,2
"maturation,",1
can,3
affect,4
subunit,2
composition,2
receptors.,1
In,13
present,4
"study,",4
we,22
investigated,2
effect,10
repetitive,1
lipopolysaccharide,1
(LPS),1
intraperitoneal,1
(i.p.),1
administration,2
(25 μg/kg/day,1
on,35
"P14,",1
"16,",1
"18),",1
mimicking,2
infectious,2
"disease,",4
expression,20
subunits,1
young,3
rats.,4
revealed,6
a,68
substantial,1
decrease,1
GluN2B,1
hippocampus,3
at,27
P23,1
using,13
Western,2
blot,2
analysis,7
real-time,1
polymerase,1
chain,1
reaction,2
assay.,2
Moderate,1
were,76
also,9
found,6
"GluN1,",1
"GluN2A,",1
GluA1,1
mRNA,7
expression.,1
The,56
LPS-treated,1
rats,12
exhibited,2
decreased,4
exploratory,1
locomotor,1
activity,5
open,2
field,1
test,2
impairment,6
spatial,1
learning,1
Morris,1
water,1
maze.,1
Behavioral,1
accompanied,3
by,45
significant,7
reduction,8
long-term,5
hippocampal,1
synaptic,2
potentiation.,1
Our,4
data,12
indicate,1
LPS-treatment,1
period,2
maturation,1
alters,2
ionotropic,2
receptor,6
gene,7
"expression,",1
disturbs,1
"plasticity,",1
"behavior.
",1
Prolonged,1
exposure,5
to,123
manganese,2
(Mn),1
may,15
lead,3
toxic,1
effects,7
central,3
nervous,1
system,4
(CNS).,1
underlying,4
neuronal,1
death,3
from,31
Mn,3
are,22
not,16
well,5
understood,1
but,7
undoubtedly,1
involve,1
inflammatory,5
processes.,1
aim,5
this,16
study,24
was,85
explore,1
long-lasting,2
intranasal,3
focusing,1
processes,1
catecholamine,1
"(dopamine,",1
norepinephrine),1
levels,10
striatum,3
hippocampus.,3
It,3
instillation,1
MnCl2,2
solution,2
once,1
day,8
90,1
days,6
leads,1
impaired,2
movement,1
gait.,1
observed,8
concentration,3
increased,17
(by,2
30,1
%),7
220,1
"%),",3
dopamine,9
(24,2
DOPAC,2
(35,1
reduced,2
"striatum,",1
(190,1
(220,1
with,137
simultaneously,1
norepinephrine,1
(30,2
Observation,1
cytokine,11
both,12
assayed,1
cytokines,4
(IL-1β,1
TNF-α),1
There,6
3-fold,1
increase,7
IBA-1,1
"mRNA,",2
2-fold,1
NFκB,1
dramatic,1
IkB,1
striatum.,1
Taken,1
"together,",1
high,3
dose,1
induces,2
neuroinﬂammation,2
neurotransmission,1
"disturbance,",1
specific,5
each,3
studied,6
brain,8
"region.
",1
Shortly,1
after,14
syphilis,2
appeared,2
Europe,1
time,7
Columbus’,1
voyage,1
New,1
"World,",1
big,1
"pox,",1
as,25
it,4
often,2
"known,",1
became,1
serious,1
issue,1
Russia,1
"diagnosis,",1
"treatment,",2
prevention.,1
Members,1
Russian,5
royal,1
family,1
made,3
aware,2
disease,17
adolescence,1
onward.,1
Czar,1
Peter,2
Great,2
had,13
many,4
sexual,1
contacts,1
could,5
have,8
contracted,2
any,5
number,4
sexually,2
transmitted,2
diseases,1
(STDs),1
quite,1
common,8
his,2
era.,1
"Nevertheless,",1
contributions,2
analyzed,3
available,3
sources,2
contemporary,1
"doctors,",1
later,2
medical,1
"analyses,",1
reveal,2
no,5
evidence,6
he,2
or,20
other,8
STD.,1
Most,2
"likely,",1
died,1
acute,7
renal,1
failure,1
due,2
urinary,1
tract,4
"obstruction.
",1
Upper,1
respiratory,3
world's,1
most,9
disease.,4
etiologic,1
agents,2
behind,1
upper,3
(URTIs),1
"are,",1
"fact,",1
diverse,2
set,1
pathogens,3
such,7
"influenza,",1
"parainfluenza,",1
"adenovirus,",1
"rhinovirus,",1
others.,1
More,2
than,11
200,1
known,1
be,14
involved.,1
Differential,1
diagnosis,4
viral,5
sometimes,1
complicated,1
their,8
diversity,1
similarity,1
clinical,15
presentation.,1
This,5
work,2
devoted,2
development,3
method,4
enables,1
simultaneous,2
detection,2
six,4
URTI,1
pathogens:,1
IAV;,1
IBV;,1
RSV;,1
hAdV;,1
hPIV2;,1
hPIV3.,1
Antibody,2
microarray,3
technology,1
utilized,1
accomplish,1
analysis.,2
preparation,1
protein,5
microchip,4
"creation,",1
"produced,",1
"characterized,",1
selected,1
approximately,2
50,3
monoclonal,3
antibodies;,1
aforementioned,1
"pathogens,",1
optimal,2
antibody,3
pair,1
selected.,1
A,12
"created,",1
its,4
core,1
working,1
conditions,2
optimized.,1
With,3
balance,3
between,10
convenience,1
maximal,1
assay,1
sensitivity,2
"mind,",1
one-step,1
approach,1
developed,3
accomplishing,1
ELISA-like,1
“sandwich”,1
interaction,1
manufactured,1
(antibody,1
microarray).,1
Reference,2
strains,1
used,6
establish,1
lower,10
limits,3
(LoD),1
For,3
"IAV,",1
LoD,2
0.25 ng/ml,1
total,3
protein.,2
"viruses,",1
ranged,1
1,7
2 ng/ml,1
These,4
slightly,1
better,2
those,6
standard,3
"ELISA,",1
inferior,1
PCR.,1
"Overall,",2
believe,1
good,2
alternative,1
existing,1
"methods,",2
allowing,1
relatively,1
quick,1
"(overnight),",1
"inexpensive,",1
screening,2
several,1
pathogens.,1
design,1
conducive,1
further,3
"development,",2
panel,1
expanded,1
include,2
"members.
",1
fullerene,3
"members,",1
"C60,",1
has,7
potential,5
application,2
various,2
fields,1
biomedicine,1
including,11
reactive,1
oxygen,1
species,1
(ROS),1
scavenging,2
"activity,",1
inhibiting,1
tumours,1
inactivating,1
viruses,1
"bacteria,",1
elaboration,1
diagnostic,4
targeted,1
drug,2
delivery,1
tools.,1
"However,",3
hydrophobicity,1
molecule,1
impedes,1
practical,1
"use,",3
therefore,1
actuality,1
research,7
functionalisation,1
fullerenes,1
leading,3
amphiphilic,1
derivatives,1
remains,1
important.,1
"work,",1
water-soluble,2
carboxylated,1
derivative,2
C60[C(COOH)2]3,2
studied.,2
Extensive,1
biomedical,2
investigation,1
"compound,",1
"namely,",1
binding,1
human,7
serum,1
albumin,1
"(HSA),",1
radical,1
diphenylpicrylhydrazyl,1
(DPPH),1
"radical,",1
photodynamic,1
"properties,",1
cytotoxicity,1
embryonic,1
kidney,1
(HEK293),1
cell,7
"line,",1
erythrocytes',1
"haemolysis,",1
platelet,1
"aggregation,",1
genotoxicity,1
peripheral,6
mononuclear,1
cells,5
(PBMC),1
conducted.,1
"Moreover,",2
dynamic,3
structural,2
characteristics,1
C60[C(COOH)2]3–H2O,1
binary,1
obtained,4
molecular,5
(MD),1
"method,",1
size,6
distribution,1
associates,1
"measured.
",1
"Aims
",1
our,8
single-center,1
retrospective,2
evaluated,4
whether,1
level,13
different,5
checkpoint,6
molecules,3
bone,5
marrow,5
biopsies,2
course,3
patients,55
myelodysplastic,2
syndrome,2
"(MDS).
",1
Methods,1
"results
",1
consecutive,2
cohort,8
55,2
MDS,2
treated,7
center,1
2003,1
2018,1
technique,1
able,2
detect,1
following,2
antigens:,1
"PD-1,",2
"PD-L1,",1
"PD-L2,",2
"LAG-3,",1
"Gal-9,",1
"TIM-3,",1
CD80.,1
association,6
3-year,3
overall,8
relapse-free,3
survival,13
time-to-progression,1
analyzed.,1
Intensive,1
TIM-3,2
100%,1
cases.,1
"Also,",1
"cases,",1
moderate,1
Gal-9,1
observed.,2
follow-up,8
progression,4
seen,1
72.9%,1
CD80,2
52.1%,1
low,5
(p=0.04).,1
CTLA4,1
ligands,2
co-expressed,1
majority,2
patients.,4
General,1
ligand,2
associated,14
incidence,4
progression:,1
67.2%,1
"progressed,",1
while,5
group,19
only,9
33.3%,1
cases,3
(p=0.059).,1
"CD80,",1
"TIM3,",1
blasts,1
risk,10
according,2
IPSS,1
IPSS-R,1
"scales.
",1
"Conclusions
",4
preliminary,2
underlined,1
heterogeneous,1
immune,6
warrants,1
studies,4
define,1
heterogeneity,1
develop,3
treatment,13
"approaches.
",1
"Background
",4
COVID-19,9
pandemic,4
broadly,1
disrupted,1
non-invasive,1
stimulation,3
(NIBS).,1
rapid,3
onset,5
societal,1
disruption,1
evolving,1
regulatory,4
restrictions,2
allowed,1
systematic,3
planning,1
how,2
continue,1
throughout,1
restarted,1
abated.,1
urgency,1
provide,3
NIBS,9
intervention,1
neurological,3
mental,3
health,4
"indications,",1
catalyst,1
fundamental,1
"research,",1
dampened,1
parallel,1
efforts,1
address,2
life-threatening,1
aspects,1
COVID-19;,1
rather,1
need,4
heightened,1
mitigate,1
consequences,1
related,2
"COVID-19.
",1
"Objective
",3
To,6
facilitate,1
re-establishment,1
access,2
services,2
operations,3
current,4
future,4
"outbreaks,",1
discuss,3
framework,1
balancing,1
importance,3
safety,4
"considerations,",1
addressing,3
needs,1
all,4
stakeholders.,1
focus,2
Transcranial,1
Magnetic,1
Stimulation,4
(TMS),1
intensity,2
transcranial,3
Electrical,1
(tES),1
-,1
Direct,1
Current,2
(tDCS),1
Alternating,1
"(tACS).
",1
"Methods
",11
consensus,1
paper,2
provides,1
guidelines,1
practices,1
managing,2
reopening,1
clinics,1
laboratories,1
through,4
immediate,1
ongoing,2
stages,5
COVID-19.,1
document,1
reflects,1
experts,1
domain-relevant,1
expertise,1
spanning,1
"technology,",1
"services,",1
basic,2
–,1
international,1
perspective.,1
outline,1
"aspects,",1
"resources,",1
"optimization,",1
accommodations,1
"demographics.
",1
"Results
",10
model,4
based,3
three,8
phases,1
(early,1
"impact,",1
"practices,",1
preparation),1
11-step,1
checklist,1
(spanning,1
removing,1
streamlining,1
in-person,1
"protocols,",1
incorporating,1
"telemedicine,",1
COVID-19-associated,1
adverse,7
events),1
proposed.,1
Recommendations,1
implementing,1
social,1
distancing,1
sterilization,1
"equipment,",1
considerations,3
positive,2
populations,2
"comorbidities,",1
regarding,3
resource,1
era,1
outlined.,1
specifically,1
(sub-)populations,1
"pediatric,",1
"stroke,",1
"addiction,",1
elderly.,1
Numerous,2
case-examples,1
across,1
world,2
"described.
",1
"Conclusion
",7
"evident,",1
"urgent,",1
maintain,1
"pandemic,",1
anticipating,1
waves,1
mind.,1
proposed,1
robust,1
structured,1
strategy,1
aims,2
anticipated,1
challenges,1
maintaining,1
scientific,1
rigor,1
"risk.
",2
Background:,1
Data,1
genetic,3
markers,4
determine,2
prognosis,2
multiple,7
sclerosis,2
(MS),1
still,2
limited.,1
galanin,3
polymorphism,5
rs948854,5
MS,2
been,7
demonstrated,9
earlier.,1
Objectives:,1
confirm,1
earlier,2
findings,3
distinct,1
previously,1
"patients,",3
characterized,5
one,5
candidates,1
stratification,1
MS.,1
Methods:,1
assess,1
rate,3
"progression,",1
severity,5
score,2
(MSSS),1
Age,1
Related,1
Multiple,1
Sclerosis,1
Severity,1
(ARMSS),1
"used,",1
along,2
Progression,1
Index,1
(PI).,1
Results:,1
minor,4
allele,4
"revealed,",1
confirming,1
findings.,2
An,4
proportion,1
MSSS > 5,1
(high,1
progression),1
among,3
G,1
carriers,2
(genotypes,1
AG,1
GG),1
compared,19
AA,1
genotype.,1
"Furthermore,",2
age,11
correlated,3
MSSS,1
value,1
late,5
(>30,1
years).,1
Conclusion:,1
"Collectively,",1
support,1
contribution,2
"MS.
",1
"Summary
",2
"Purpose
",1
describe,1
analyze,2
patient,4
recurrent,4
idiopathic,4
exudative,2
polymorphous,2
vitelliform,3
maculopathy,1
"(AEPVM),",1
followed,3
"detail,",1
propose,1
"algorithm.
",1
"Design
",1
Retrospective,1
observational,1
"analysis.
",1
"Patient
",1
adult,3
male,2
diagnosed,1
AEPVM,2
who,5
two,6
relapses,1
12-month,1
eight,1
years,6
initial,4
"onset.
",1
Review,3
"charts,",1
multimodal,2
"imaging,",1
electrophysiology,2
repeatedly,1
underwent,2
complete,2
ophthalmic,1
"examinations,",1
best-corrected,1
visual,4
acuity,1
testing,2
"(BCVA),",1
slit-lamp,1
fundus,5
examinations;,1
digital,1
"photography,",1
time-domain,1
optical,1
coherence,1
tomography,1
(OCT),1
2009,1
(Stratus,1
"OCT,",1
Carl,1
Zeiss,1
"Meditec,",1
USA),1
spectral-domain,1
OCT,1
2017–2018,1
"(Spectralis-OCT,",1
Heidelberg,1
"Engineering,",2
"Germany),",1
together,3
autofluorescence,3
"(FAF),",1
fluorescein,1
angiography,2
"(FA),",1
indocyanine,1
green,1
"(ICGA),",1
HRA2,1
(Heidelberg,1
Germany);,1
microperimetry,1
(MP-1,1
"microperimeter,",1
"Nidek,",1
Japan).,1
Laser,1
flare,1
photometry,1
(Kowa,1
"FM-600,",1
Japan),1
"performed.
",1
Main,1
outcome,5
"measures
",1
Clinical,1
features,4
"AEPVM,",2
algorithm,1
rare,1
"cases.
",2
Case,1
report,2
25-year-old,1
Caucasian,2
typical,1
serous,2
neuroepithelial,1
detachment,1
irregular,1
retinal,4
"elevations,",1
ophthalmoscopically,1
resembling,1
"folds,",2
subsequent,1
subretinal,1
accumulation,2
characteristic,1
yellow–white,1
deposits.,1
Features,1
case,3
rarely,1
"described,",1
even,2
yet,1
"reported,",1
indocyanine-,1
fluorescein-negative,1
intraretinal,1
cystic,1
"changes,",1
optic,1
disc,1
hyperfluorescence,1
"FA,",1
elevations,1
choroidal,1
"thickness,",1
lack,1
"recovery,",1
very,5
slow,2
anatomical,1
improvement,2
relapses.,1
Bimonthly,2
evaluation,3
SD-OCT,2
informative,1
demonstrating,1
evolution,1
pathological,1
"signs.
",1
chronic,3
condition,1
uncertain,1
outcomes.,1
variable,1
presentations,1
depending,1
stage,2
manifestations,3
imaging,2
pathologic,1
process,1
overlap.,1
Patients,6
should,4
occurs,1
"slowly,",1
if,1
all.,1
recommended,2
"ABSTRACT
",2
Allogeneic,1
hematopoietic,2
transplantation,1
(HCT),1
high-risk,1
T,2
lymphoblastic,1
leukemia,2
(T-ALL).,1
without,6
HLA-identical,1
"donor,",1
haploidentical,2
(haplo-),1
HCT,1
becoming,1
source,1
stem,2
donation.,1
scarce,1
predictive,2
factors,1
setting.,1
identified,3
122,2
adults,1
(20%,1
female;,1
median,9
"age,",4
31,2
years;,2
"range,",1
18,5
68,2
years),1
T-ALL,1
haplo-HCT,3
post-transplantation,2
cyclophosphamide,2
(ptCy),1
2010,1
2017.,1
duration,4
living,1
23,1
months.,4
2-year,3
incidences,1
relapse,2
nonrelapse,2
mortality,3
45%,1
"21%,",2
respectively.,5
leukemia-free,2
"(LFS),",1
"(OS),",1
graft-versus-host,2
(GRFS),1
"34%,",1
"42%,",1
"27%,",1
LFS,5
OS,7
highly,3
influenced,2
status,3
"transplantation,",1
being,1
49%,1
"55%,",1
"respectively,",3
first,8
remission,1
(CR1);,1
34%,1
"50%,",1
second,4
CR,1
(CR2);,1
8%,1
"12%,",1
active,5
On,2
multivariate,2
"analysis,",2
OS.,2
Transplantation,3
CR2,1
negatively,2
affected,5
"LFS,",1
whereas,4
"conclusion,",1
ptCy,1
produced,1
encouraging,1
results,8
challenging,1
particularly,1
when,2
performed,3
CR.,1
Despite,2
limitation,1
small,2
sample,1
"size,",1
type,2
"conditioning,",1
calling,1
into,4
question,1
body,2
irradiation-based,1
myeloablative,1
conditioning,4
"setting.
",1
"HIV,",1
heavy,5
"drinking,",1
smoking,5
pro-inflammatory,1
coronary,1
heart,1
(CHD).,1
Interventions,1
reduce,4
alcohol,8
"smoking,",2
HIV-positive,4
people,1
"inflammation,",2
CHD,2
risk.,1
Varenicline,1
cytisine,3
proven,2
therapies,1
cessation,2
consumption.,1
comparative,3
efficacy,7
varenicline,2
consumption,2
"tested,",1
nor,2
effectiveness,1
reported,5
"smoking.
",1
describes,1
protocol,2
Studying,1
Partial,1
agonists,1
Ethanol,1
Tobacco,1
Elimination,1
Russians,1
HIV,2
(St,1
PETER,2
"HIV),",1
four-arm,1
parallel-group,1
randomized,5
controlled,3
trial,3
comparing,2
"varenicline,",1
"cytisine,",1
nicotine,1
replacement,1
therapy,8
"(NRT).
",1
recruiting,1
four,1
hundred,1
drinking,3
smokers,2
interested,1
cutting,1
down,1
and/or,2
tobacco,2
St.,2
"Petersburg,",2
Russia.,1
Participants,1
randomly,1
assigned,1
receive,2
either,3
varenicline + NRT,1
"placebo,",2
placebo + active,2
"NRT,",1
cytisine + NRT,1
NRT.,1
All,1
participants,5
evidence-based,1
counseling,1
"medication,",1
placebo.,1
Outcomes,1
are:,1
1),4
%,15
past,1
month,1
(primary,2
months),2
craving;,1
2),1
cigarettes,1
per,3
3,5
7-day,1
point,2
prevalence,1
abstinence,1
and;,1
3),1
"risk,",1
St,1
addresses,1
paucity,1
guide,1
"smokers.
",1
Here,4
evaluate,3
mast,3
infection,5
influenza,5
A/H5N1,2
virus,2
immunized,3
mice.,2
CBA,1
mice,4
intramuscularly,1
formalin-inactivated,1
A/Vietnam/1194/2004,1
(H5N1)NIBRG-14,1
(H5N1).,1
Serum,2
samples,2
"7,",1
"12,",1
"14,",2
21,2
immunization.,1
At,3
infected,1
intranasally,1
A/Indonesia/5/2005,1
(H5N1)IDCDC-RG2,1
(H5N1),1
half,1
animals,1
receiving,2
mixture,1
antihistamines.,1
67%,1
vaccinated,1
protected,1
lethality,1
43%,1
PBS-immunized,1
group.,2
Administration,2
antihistamines,1
up,1
85%–95%.,1
Immunohistochemical,1
examination,3
CD117,1
staining,2
lungs,2
larger,1
quantity,1
activated,1
mock-immunized,1
histamine,3
blood.,1
experimental,1
involvement,2
they,4
produce,1
incomplete,1
formation,1
response,12
vaccination,1
mismatch,1
vaccine,1
"viruses.
",1
Gestational,2
methylazoxymethanol,1
acetate,1
(MAM),1
produces,1
offspring,1
phenotype,4
relevant,1
"schizophrenia,",1
positive-,1
negative-like,1
"symptoms,",1
"deficits,",1
dopaminergic,1
"dysfunction,",1
abnormalities.,1
show,2
prenatally,1
MAM,5
gestational,8
17,3
display,1
D3,6
(D3),1
prefrontal,1
cortex,1
"(PFC),",1
nucleus,1
"accumbens,",1
D2,2
(D2),1
exclusively,1
PFC.,1
change,1
blood,9
perfusion,1
circle,1
Willis,1
"hippocampus,",1
paralleled,1
enlargement,1
lateral,1
"ventricles,",1
detected,4
magnetic,1
resonance,1
(MRI),1
techniques.,1
Peripubertal,1
non-euphoric,1
phytocannabinoid,1
cannabidiol,4
(30 mg/kg),1
postnatal,1
(PND),1
19,3
PND,1
39,1
reverse,1
exposed,2
rats:,1
i),1
up-regulation,1
(only,1
partially,1
prevented,1
haloperidol,1
0.6 mg/kg/day);,1
ii),1
regional,1
flow,7
Molecular,1
modelling,1
predicted,1
bind,1
preferentially,1
"receptor,",1
where,1
act,1
partial,1
agonist,1
conformation,1
"ionic-lock,",1
conserved,1
GPCRs.,1
"summary,",1
demonstrate,1
altered,2
model;,1
however,1
transcript,1
likely,2
suggesting,1
might,1
contribute,3
schizophrenia,2
symptoms,2
represent,1
unexplored,1
target,1
antipsychotic,1
"cannabidiol.
",1
timing,2
immunosuppressive,1
combination,1
(PTCY),1
transplant,1
(haplo-HSCT),1
standardized.,1
schedules,1
immunosuppression,3
haplo-HSCT,2
509,1
PTCY,4
+3,3
+4,1
tacrolimus,1
(group,3
1;,1
"n = 215),",1
cyclosporine,1
(CSA),1
mycophenolate,1
mofetil,1
(MMF),1
+5,3
2;,1
"n = 170),",1
CSA + MMF,2
0,1
3;,1
n = 124).,1
Compared,1
2,9
"groups,",1
younger,1
(median,1
46,1
P = .02),1
more,7
received,5
(77%;,1
P,1
<,1
.01),1
regimen,1
containing,1
"thiotepa,",1
"fludarabine,",1
busulfan,1
(84%;,1
P<,1
.01).,1
"years,",2
44%,1
"1,",3
48%,1
"2,",3
59%,1
(P=,5
.15);,1
(LFS),1
"43%,",1
"46%,",1
53%,1
.05);,1
refined,1
"disease-free,",1
(rGRFS),1
"33%,",1
"39%,",1
36%,1
(P = .02).,1
grade,4
II-IV,1
GVHD,2
25%,1
39%,1
18%,1
(P<,1
.01);,1
"25%,",1
24%,1
.50);,1
"36%,",1
"37%,",1
26%,1
.02);,1
"26%,",1
"20%,",1
21%,1
.35).,1
start,2
+1,1
(hazard,1
ratio,4
"[HR],",1
.58;,1
P=,1
.02),1
improved,2
rGRFS,1
"(HR,",1
.62;,1
P = .02).,1
outcomes,2
PTCY.,1
administered,2
improves,2
"rGRFS.
",1
Immune,2
pivotal,1
synucleinopathy,2
Parkinson’s,2
(PD),3
mediated,2
neurotoxic,1
alpha-synuclein.,1
limited,1
another,1
dementia,6
Lewy,1
bodies,1
(DLB).,1
Recent,1
impairment.,1
aimed,2
estimate,3
plasma,11
profile,3
synucleinopathies,3
(PD,1
"(PDD),",1
DLB).,1
Plasma,2
(interferon-gamma,1
"(IFN-gamma),",1
interleukin,1
(IL)-4,1
"(IL-4),",1
"IL-6,",2
"IL-10,",3
tumor,2
necrosis,1
factor,2
alpha,1
"(TNF-alpha),",1
monocyte,1
chemoattractant,1
protein-1,1
(MCP-1)).,1
estimated,1
16,3
"DLB,",1
"PDD,",2
28,1
PD,15
individuals,2
disorders,1
(controls),1
Luminex,1
array,2
system.,1
Cognitive,1
assessed,7
Mini–Mental,1
State,1
Examination,1
(MMSE).,1
TNF-alpha,1
IL-6,2
elevated,1
"(DLB,",1
PDD),1
controls,7
IL-10,1
PDD,2
(p < 0.05).,1
IFN-gamma,1
"(p < 0.001,",1
"p = 0.026,",1
respectively),2
DLB,2
(p = 0.032).,1
"PD,",6
MCP-1,1
(p < 0.001).,1
same,2
"time,",1
differences,2
"TNF-alpha,",1
found.,2
pronounced,3
"demetia.
",1
Many,1
metastatic,2
non-small-cell,2
lung,2
cancer,1
(mNSCLC),1
experience,1
first-,1
second-line,1
treatment;,1
options,1
required,2
"ARCTIC,",1
phase,2
"III,",1
"randomized,",1
open-label,1
durvalumab,8
±,1
tremelimumab,7
versus,8
care,1
(SoC),4
≥,1
third-line,2
"mNSCLC.
",1
"methods
",1
ARCTIC,1
comprised,1
independent,1
sub-studies.,1
Study,7
A:,2
126,1
≥25%,1
(TCs),1
expressing,1
programmed,1
ligand-1,1
(PD-L1),1
(1,1
:,3
[up,1
12,3
months,13
10 mg/kg,1
every,1
weeks,10
(q2w)],1
SoC.,1
B:,2
469,1
PD-L1,3
TC,3
<25%,1
(3 :,1
durvalumab +,3
(12,1
20,1
mg/kg +,1
mg/kg,4
q4w,2
then,2
34,3
10,3
"q2w),",2
"SoC,",1
(up,1
24,1
q12w).,1
Primary,1
end,4
points:,1
(OS),1
progression-free,2
(PFS),1
SoC,4
(study,2
A;,1
descriptive,1
only),1
"B).
",2
11.7,1
(durvalumab),3
6.8,1
{hazard,1
(HR),1
0.63,1
[95%,1
confidence,2
interval,2
"(CI),",1
0.42–0.93]};,1
PFS,5
3.8,1
2.2,1
[HR,3
0.71,1
(95%,6
"CI,",3
0.49–1.04)].,1
11.5,1
(durvalumab +,2
tremelimumab),2
8.7,1
0.80,1
0.61–1.05);,1
P =,2
0.109].,1
Median,2
3.5,1
groups,5
0.77,1
0.59–1.01);,1
0.056].,1
Treatment-related,1
3/4,1
events:,1
9.7%,1
44.4%,1
(SoC;,2
A),1
22.0%,1
36.4%,1
heavily,1
pretreated,1
"mNSCLC,",1
clinically,2
meaningful,2
improvements,2
(patients,2
≥25%);,1
numerical,1
<25%).,1
Safety,2
profiles,2
consistent,2
previous,5
"studies.
",2
Trial,1
"registration
",1
Clinicaltrials.gov,1
identifier:,1
"NCT02352948.
",1
"Objectives
",3
Because,1
reference,4
intervals,2
(RIs),1
biochemistry,2
analytes,3
matched,2
population,3
"defined,",1
joined,1
global,2
values,3
(RVs),1
coordinated,1
IFCC,2
Committee,1
Intervals,1
Decision,1
Limits,1
"(C-RIDL).
",1
According,1
C-RIDL,1
harmonized,1
"protocol,",1
793,1
healthy,1
volunteers,2
recruited,2
"Saint-Petersburg,",1
"Moscow,",1
Yekaterinburg.,1
tested,1
analytes.,2
Sources,1
variation,2
RVs,4
explored,1
regression,2
partitioning,1
sex,2
judged,1
deviation,1
ANOVA.,1
Latent,1
abnormal,1
exclusion,1
(LAVE),1
applied,1
influence,2
metabolic,2
inappropriate,1
sampling,1
conditions.,1
RIs,5
computed,2
parametric,1
"method.
",1
No,3
appreciable,1
between-city,1
Partition,1
Age-related,1
"analytes,",2
especially,2
females.,1
trend,1
exaggerated,1
nutritional,2
closely,1
mass,1
index,1
"(BMI),",1
because,2
BMI,1
increases,2
prominently,1
age.,4
"Therefore,",1
BMI > 28 kg/m2,1
excluded,2
determining,1
age-specific,2
RIs.,1
LAVE,1
effective,1
lowering,1
"markers.
",1
established,1
biochemical,2
up-to-date,1
methods,1
detailed,1
consideration,2
RVs.,1
similar,1
participating,1
"countries.
",1
Adequate,1
transplacental,1
passage,1
maternal,8
thyroid,10
hormone,2
important,3
normal,6
fetal,3
growth,1
development.,1
Maternal,3
overt,1
hypothyroidism,4
hyperthyroidism,1
"birthweight,",3
knowledge,1
gaps,1
remain,2
subclinical,4
function,9
abnormalities,1
birthweight—both,1
general,1
third,3
trimester,3
pregnancy.,2
examine,1
associations,1
"birthweight.
",1
review,2
individual-participant,3
"meta-analysis,",1
searched,1
MEDLINE,1
"(Ovid),",1
"Embase,",1
Web,1
"Science,",1
Cochrane,1
Central,1
Register,2
Controlled,1
"Trials,",1
Google,1
Scholar,1
inception,1
Oct,1
"15,",1
"2019,",1
prospective,3
pregnancy,2
issued,1
invitations,1
identify,1
authors,2
join,1
Consortium,1
Thyroid,1
Pregnancy.,1
"pregnancies,",1
in-vitro,1
"fertilisation,",1
pre-existing,1
medication,1
"usage,",1
"miscarriages,",1
stillbirths.,1
main,1
(SGA),1
"neonates,",2
large,1
newborn,1
birthweight.,3
analysed,1
mixed-effects,1
models,2
adjusting,1
"BMI,",1
"ethnicity,",1
"parity,",1
"sampling,",1
"sex,",1
birth.,1
pre-registered,1
International,1
Prospective,1
Systematic,1
"Reviews,",1
"CRD42016043496.
",1
"Findings
",1
2526,1
published,1
"reports,",2
36,1
cohorts,3
met,1
inclusion,1
criteria.,1
15,3
agreed,1
"participate,",1
five,1
unpublished,1
datasets,1
"added,",1
giving,1
48 145,1
mother–child,1
pairs,1
"exclusions,",1
whom,1
1275,1
(3·1%),1
(increased,1
stimulating,1
[TSH],1
free,1
thyroxine,1
[FT4]),1
929,1
(2·2%),1
isolated,4
hypothyroxinaemia,3
(decreased,1
FT4,3
TSH).,1
higher,7
SGA,4
euthyroidism,2
(11·8%,1
vs,2
10·0%;,1
adjusted,2
difference,7
"2·43%,",1
95%,1
CI,1
0·43,1
4·81;,1
odds,1
[OR],1
"1·24,",1
1·04,1
1·48;,1
p=0·015),1
mean,2
birthweight,4
(mean,2
−38,1
"g,",2
−61,1
−15;,1
"p=0·0015),",1
measurement,2
second.,1
Isolated,1
(7·3%,1
"10·0%,",1
"−2·91,",1
−4·49,1
−0·88;,1
OR,1
"0·70,",1
0·55,1
0·91;,1
p=0·0073),1
45,1
73;,1
p=0·0012).,1
Each,2
SD,2
TSH,2
6,2
g,2
(–10,1
−2;,1
"p=0·0030),",1
estimates,1
women,2
peroxidase,1
negative,1
(pinteraction=0·10).,1
(–25,1
−17;,1
"p<0·0001),",1
"second.
",1
"Interpretation
",1
"inverse,",1
dose-response,1
(even,1
within,2
range),1
advance,1
understanding,3
complex,3
relationships,1
"outcomes,",1
prompt,1
careful,1
risks,1
benefits,1
levothyroxine,1
"pregnancy.
",1
"Funding
",1
Netherlands,1
Organization,1
Scientific,1
Research,1
(grant,1
"401.16.020).
",1
Lorlatinib,4
third-generation,1
tyrosine-kinases,1
inhibitor,2
(TKI),1
targeting,1
ALK/ROS1,2
fusions.,1
FDA,1
approved,1
lorlatinib,1
TKI-pretreated,1
ALK(+),5
"NSCLC,",1
approval,1
ROS1(+),4
pending.,1
largest,1
real-world,1
NSCLC,4
harboring,1
rearrangements,1
"lorlatinib.
",1
123,2
enrolled,3
retrospectively,1
(data,2
cut-off,1
1/1/2019).,1
program,1
therapy.,1
Outcome,1
defined,1
investigator,1
upon,1
RECIST,1
1.1,1
"criteria.
",1
106,1
8,3
countries.,1
included,2
"males,",2
73,1
never-smokers,2
metastases.,3
Extracranial,1
(EC),1
intracranial,2
(IC),1
rates,2
(RR),1
60,1
62,2
"%,",1
control,3
(DCR),1
91,1
88,1
Mean,1
(DoT),1
23.9 ± 1.6,1
(mOS),1
89.1 ± 19.6,1
ROS1,1
53,1
65,2
EC,1
IC,1
RR,1
67,1
DCR,1
92,1
78,1
DoT,2
18.1 ± 2.5,1
mOS,3
90.3 ± 24.4,1
significantly,3
line,1
parameters.,1
events,4
edema,1
(48,1
hyperlipidemia,1
(47,1
weight,1
gain,1
(25,1
fatigue,1
%).,1
CNS,1
1–2,2
"patients.
",1
shows,1
outstanding,1
EC/IC,1
ALK/ROS1(+),1
NSCLC.,2
89 ± 19,1
supports,1
90 ± 24,1
unprecedented,1
"NSCLC.
",1
Diabetes,2
mellitus,2
dysregulation,1
complications.,1
50%,1
diabetes,1
suffer,1
diabetic,5
"polyneuropathy,",1
involves,1
presence,3
nerve,7
dysfunction,3
symptoms.,1
new,2
synthetic,1
arginine-rich,2
exendin-4,1
(Peptide,1
D),1
complications,1
caused,1
"diabetes,",1
"neuropathy,",1
induced,1
administering,1
streptozotocin,1
(STZ).,1
Three,1
Peptide,4
D,4
"(0.1,",1
10 μg/kg).,1
Byetta®,2
(1 μg/kg),1
80,1
days.,1
Neuropathic,1
pain,1
tactile,3
allodynia.,2
STZ-treated,2
showed,3
allodynia,1
unlike,1
naïve,3
animals.,3
histological,1
diameter,2
sciatic,3
fibers,1
smaller,2
IHC,1
myelin,1
(MBP),1
Byetta®.,1
resulted,1
MBP,1
myelinated,1
fibers.,1
poly-arginine,1
peptides,1
promising,1
"polyneuropathies.
",1
pattern,1
auditory,4
preterm,3
children,13
"birth.
",1
"design
",1
longitudinal,1
"study.
",1
involved,1
271,1
aged,1
old.,1
Children,1
divided,2
groups:,2
70,1
birth,1
32–36,1
(Group,2
201,1
22–31,1
2).,1
Hearing,1
"ABR,",1
"ASSR,",1
"OAE,",1
behavioral,1
"audiometry,",1
pure,1
tone,1
audiometry.,1
"Additionally,",1
some,2
"children,",1
"CT,",1
"MRI,",1
GBJ2,1
evaluations,1
performed.,1
Assessments,1
hearing,7
3–4,2
times,4
year,4
under,2
age;,2
2–3,2
5,2
over,1
Infants,2
problems,1
examined,1
"life,",1
annual,1
examinations,1
"aged.
",1
SNHL,1
ANSD,2
(25.7%),1
64,1
(31.8%),1
Group,7
occurrence,1
assessment,2
(p > 0.05).,1
Further,1
children:,2
child,1
1.,1
Four,1
kinds,1
noted:,1
recovery,3
ANSD;,1
loss;,1
transformation,1
"SNHL,",1
vice,1
versa.,1
"factors,",1
discussed,2
"article.
",1
prematurely,1
born,3
tends,1
"unstable,",1
"infants,",1
deteriorate,1
improve.,1
before,3
weeks’,1
gestation,4
require,1
least,4
until,1
Caution,1
advised,1
cochlear,1
implantation,1
32,1
"age.
",1
"Introduction
",2
"II,",1
single-arm,1
ASCEND-3,1
ceritinib,3
anaplastic,1
lymphoma,1
kinase,1
(ALK),1
(ALKi)–naive,1
ALK-rearranged,1
lines,2
chemotherapy.,1
"Here,",3
final,1
"results.
",1
Eligible,1
(including,1
asymptomatic,1
neurologically,1
stable,1
metastases),1
oral,1
(750,1
"mg/day,",1
fasted).,1
primary,1
investigator-assessed,2
(ORR).,1
Secondary,1
points,2
Blinded,2
Independent,2
Committee–assessed,2
ORR;,1
investigator-,1
"rate,",2
"response,",3
(PFS);,1
(OS);,1
safety.,1
Exploratory,1
patient-reported,1
"outcomes.
",1
Of,2
124,1
"enrolled,",1
(98.4%),1
antineoplastic,1
medications,2
(31,1
[25.0%],1
"regimens),",1
49,1
(39.5%),1
baseline,2
cutoff:,1
January,1
"22,",1
2018),1
52.1,1
"(range,",1
48.4–60.1),1
ORR,1
67.7%,1
[CI]:,1
"58.8–75.9),",1
16.6,1
CI:,2
11.0–23.2).,1
51.3,1
42.7–55.3).,1
(all,2
"grades,",1
≥60%,1
all-causality),1
diarrhea,1
"(85.5%),",1
nausea,1
"(78.2%),",1
vomiting,1
(71.8%).,1
(14.5%),1
event,1
discontinuation.,1
Health-related,1
quality,1
maintained,1
"treatment.
",1
Ceritinib,1
prolonged,1
"OS,",1
"PFS,",1
chemotherapy-pretreated,1
(at,1
"lines),",1
ALKi-naive,1
ALK+,1
possibilities,1
angioprotection,1
osteonecrosis,1
given,3
bisphosphonates.,1
"experiment,",1
27,1
injected,1
saline;,1
zoledronic,4
acid,5
weeks;,1
"weeks,",1
added,1
doses,1
sulodexide,2
weeks.,2
After,1
constructed,1
teeth,1
extracted.,1
velocity,1
linear,1
periodontal,1
area,1
extracted,1
tooth,1
laser,1
high-frequency,1
Doppler,1
ultrasound,1
(with,1
vasoactive,1
substance,2
acetylcholine,1
3%,1
1min).,1
structure,1
bony,3
tissues,1
head,1
"tomography,",1
saline,2
microcirculation,4
use,1
acid.,1
mucous,4
membranes,3
"and,",1
greater,1
"extent,",1
tissue.,1
Zoledronic,1
causes,1
periosteal,1
"disorders,",1
includes,1
cellular,2
component,1
(impaired,1
endothelium-dependent,1
vasodilation,3
membrane,1
vessels),1
reducing,1
tissues.,1
"Sulodexide,",1
"however,",1
restoration,1
reduces,1
"osteonecrosis.
",1
subcortical,1
pathways,3
motor,6
spinal,6
cord,4
injury,2
(SCI),2
animal,1
models.,1
descending,1
interlimb,3
lumbosacral,4
excitability,2
SCI,5
"humans.
",1
Ulnar,1
transcutaneous,1
electrical,2
condition-test,1
paradigm,1
connections,1
linking,2
cervical,1
segments,1
non-injured,1
(n=15),1
injured,1
(n=18),1
"participants.
",1
Potentiation,1
spinally,2
evoked,2
responses,3
(sEMRs),1
ulnar,2
7/7,1
volitional,3
leg,2
muscle,2
"activation,",2
6/11,1
activation.,1
"six,",1
sEMRs,1
rostral,1
innervation,1
entry,1
"zones.
",1
Descending,1
modulation,1
pools,1
via,2
projections,1
exist,1
despite,1
absence,1
"activation.
",1
"Significance
",1
Evaluation,1
"sub-clinical,",1
spared,1
residual,1
"function,",1
plasticity,1
"rehabilitation..
",1
Macrophages,2
participate,1
regulation,1
morphogenetic,1
placenta.,1
roles,5
unclear,1
placental,8
macrophages,6
(Hofbauer,1
cells).,1
characterize,1
steps,2
production,6
(intracellular,1
synthesis,1
secretion),1
compare,1
secretory,1
villous,2
"tissue.
",2
tissue,2
placentas,1
pregnancies,1
9–12,1
38–40,1
gestation.,1
Intracellular,1
determined,1
cytometry,1
antibodies.,1
Secreted,1
quantified,1
cytometric,1
bead,1
"ELISA.
",1
Two,2
patterns,6
macrophages.,1
Cytokines,2
"(IL-1,",1
"IL-8,",1
TNFα),1
basal,2
stimulated,1
endotoxin.,1
"(IL-11,",1
"IL-17A,",1
"IL-17F,",1
"TGF-β,",1
VEGF),1
constitutive,1
did,2
respond,1
stimulation.,1
age-dependent,1
observed:,1
secretion,3
TNFα,1
IL-8,1
IL-11,1
IL-17,1
third-trimester,1
first-trimester,1
cells.,1
Comparison,1
suggested,1
intraplacental,1
extraplacental,2
"production.
",1
"Discussion
",1
would,1
safe,1
assume,1
"production,",1
correspond,1
macrophages:,1
“immune”,1
“morphogenetic”.,1
attenuated,1
supposedly,1
local,1
"levels,",1
confined,1
Mutations,1
glucocerebrosidase,1
(GBA),1
cause,1
Gaucher,2
"(GD),",1
lysosomal,4
storage,1
disorder,1
"(LSD),",1
Parkinson's,4
(PD).,2
Lysosome,1
functionality,1
plays,1
extracellular,1
vesicles,2
(EVs),1
content.,1
EVs,4
GD,5
terms,1
"amounts,",1
"distribution,",1
cargo.,1
sequential,1
centrifugation,1
сryo-electron,1
microscopy,1
"(cryo-EM),",1
nanoparticle,1
tracking,1
"(NTA),",1
light,1
scattering,1
(DLS).,1
exosomal,3
HSP70,2
tetrasponins,1
cytometry.,1
Protein,1
profiling,2
mass-spectrometry,1
(shotgun,1
analysis).,1
morphology,1
exosomes,4
derived,1
cryo-EM,1
DLS,1
"(р<0.0001,",1
"p < 0.001,",1
confirmed,1
mode,1
NTA,1
(p < 0.02).,1
Cryo-EM,1
double,1
multilayer,1
enriched,1
surface,1
"(CD9,",1
"СD63,",1
CD81),1
exosome-associated,1
Proteomic,1
proteins,2
pathogenesis.,1
"Thus,",2
striking,1
alteration,1
"morphology.
",1
perform,1
postural,2
neuropsychiatric,2
tremor,2
"(ET),",1
"phenotypes,",1
combined,1
ET,6
"(ET-PD).
",1
169,1
(1.0–2.0),1
111,1
advanced,3
(2.5–3.0),1
Hoehn,1
Yahr,1
"scale,",1
26,1
ET-PD,3
study.,1
Motor,1
non-motor,1
standardized,2
scales,2
"stabilometry.
",1
ETPD,3
milder,1
parkinsonism,1
posture,1
walking,1
scales.,1
"ETPD,",1
PD.,1
Using,1
"stabilometry,",1
discovered,1
indexes,2
stabilometric,2
parameters,2
although,1
"ET.
",1
conducted,2
helpful,1
differential,2
diagnosis.,1
helps,1
expand,1
"ET-PD.
",1
recent,1
highlighted,1
autophagy,2
pathway,2
(ALP),1
Genes,1
GBA,1
"LRRK2,",1
harbor,1
mutations,1
ALP.,2
"α-synuclein,",1
encoded,1
SNCA,2
"gene,",1
degraded,1
mainly,1
"ALP,",2
mutations/multiplications,1
chaperone,1
ALP,3
functions.,1
PD-related,1
"genes,",1
"PRKN,",1
"PINK1,",1
"TMEM175,",1
"SMPD1,",1
"CTSD,",1
CTSB,1
"more,",1
Understanding,1
relationship,1
crucial,1
uncovering,1
long-awaited,1
neuroprotective,1
therapies.,1
"review,",1
will,3
"(other,",1
atypical,1
forms,1
"Parkinsonism,",1
review).,1
genes,3
"proteins,",1
"PD.
",1
elucidate,1
dynamical,3
complexity,3
impulse,1
sensory,2
neurons,5
emergence,2
antinociceptive,3
painful,1
stimulus.,1
solve,1
problem,1
bifurcation,1
enabled,1
us,1
relations,1
nociceptive,2
neuron,1
effect.,1
shown,1
mechanism,5
suppression,3
ectopic,1
bursting,1
discharges,2
base,1
neurons.,1
Under,1
potassium,1
"blocking,",1
connected,1
entirely,2
modification,1
activation,2
gating,1
NaV1.8,1
sodium,1
channels,1
action,2
comenic,1
non-opioid,1
analgesic,3
anoceptin.,1
explain,1
neuropathic,1
"pain.
",1
Metoclopramide,2
widely,1
abortive,1
migraine,2
advantage,1
having,1
"antiemetic,",1
properties.,1
metoclopramide,6
"migraine,",1
anti-cephalalgic,1
elucidated.,1
Taking,1
account,1
key,1
trigeminovascular,4
"pathophysiology,",1
investigate,1
neurogenic,2
dural,3
valid,1
electrophysiological,1
neurovascular,1
nociception.,1
Extracellular,1
recordings,1
second-order,1
dura-sensitive,1
trigeminocervical,1
(TCC),1
anaesthetised,1
Cumulative,1
infusion,2
(three,1
30 min,1
"intervals,",1
5 mg/kg,1
i.v.,2
"step,",2
n = 8),1
dose-dependently,1
suppressed,1
firing,1
TCC,1
"stimulation,",1
maximally,1
30%[0–49%],1
(median[Q1-Q3]),1
4%[0–30%],1
"level,",1
respectively,1
(both,1
"p = 0.001,",1
(n = 8)).,1
By,1
"contrast,",1
separate,1
cumulative,1
(5 mg/kg,1
n = 6),1
vehicle,1
(n = 6),1
p > 0.05).,1
unable,1
does,1
suppress,1
anti-migraine,1
action.,1
here,1
neurophysiological,1
therapeutic,1
"migraine.
",1
Exposure,1
lipopolysaccharidein,1
affects,1
disturbances,1
potentiation,1
functions,1
"rats,
",3
Intranasal,1
disrupts,1
metabolism,1
"hippocampus,
",1
"diseases,
",1
immunoassay,1
"pathogens,
",1
Biological,1
dynamics,1
simulation,1
"C60[C(COOH)2]3,
",1
checkpoints,1
predictor,1
"syndrome,
",1
Guidelines,1
TMS/tES,1
"pandemic,
",1
sclerosis:,1
"onset,
",1
Eight-year,1
"maculopathy,
",1
Haploidentical,2
Post-Transplantation,2
Cyclophosphamide,2
Cell,1
Acute,3
Lymphoblastic,1
Leukemia:,1
Report,1
European,2
Society,2
Blood,2
Marrow,2
Leukemia,2
Working,2
"Party,
",1
Design,1
drinkers,1
daily,1
"Russia,
",1
Mast,1
degranulation,1
release,1
influenza-sensitized,1
"mice,
",1
Altered,2
reversed,1
peripubertal,1
"treatment,
",1
Timing,1
Transplantation:,1
Comparative,1
Behalf,1
Party,1
"Transplantation,
",1
synucleinophaties,1
"dementia,
",1
ARCTIC:,1
"cancer☆,
",1
Establishing,1
major,1
population:,1
part,1
"values,
",1
Association,1
birthweight:,1
"meta-analysis,
",1
GLASS:,1
Global,1
Study:,1
real,1
"patients,
",1
Therapeutic,1
exenatide,1
neuropathy,1
Changes,1
premature,1
"study,
",1
Final,1
Overall,1
Survival,1
Other,1
Efficacy,1
Results,1
From,1
ASCEND-3:,1
Phase,1
II,1
of Ceritinib,1
ALKi-Naive,1
ALK-Rearranged,1
"NSCLC,
",1
Disorders,1
bisphosphonate,1
osteonecrosis:,1
Interlimb,1
"injury,
",1
"macrophages,
",1
"disease,
",1
Postural,1
instability,1
disturbance,1
overlapping,1
"Disease,
",1
Autophagy,1
disease;,1
"genetics,
",1
Mechanisms,1
"emergence,
",1
Influence,1
Trigeminovascular,1
Nociception:,1
Possible,1
Anti-migraine,1
Mechanism,1
"Action,
",1
